Stock info Pharming | Filter  Basic-Info

Pharming

Pharming's main office is based in Leiden. Pharming primarily operates in the biotech sector. The global biotech companies gained around 59 percent worldwide over the last 10 years. Measured since 2011 the sector is 70 percent higher and over the past 12 months (December 2015-December 2016) there is a minus of 59 percent.

The past year gave good returns for Pharming investors

Over the last 12 months (from December 2015 till December 2016), that were loss-making period for the investors in Pharming, the stock lost around 21 percent. Over the past 5 years the stock lost a massive -78,22 percent. Pharming's revenues between 2011 and 2015 were relatively stable and moved between 10,61 million euros and 10,83 million euros. Pharming's net results between 2011 and 2015 were very fluctuating and moved between -17,84 million euros and -9,96 million euros.

The Dutch company didn't pay out any dividends (in the past 5 years).

At the end of 2015 Pharming employed at around 43 people.

Pharming' balance mostly financed with equity

At the end of 2015 the biotech company's balance sheet equaled 57,68 million euros. Last year the total debt of the company was 33,84 million euros. This equals around 58,67 percent of the total balance sheet.

At the end of 2015 the market capitalization (the number of shares outstanding multiplied by the stock price) of the biotech company equaled around 114,43 million euros. At the end of 2015 the Dutch company had around 408,68 million stocks listed on the stock exchange(s).

On this page you can find all Pharming's financial reports. More information about Pharming can be found it's website. .